Heartport, Inc.

Other

Ethicon Endo-surgery, Inc.

Evalve, Inc.

Twelve, Inc.

Pivot Medical, Inc.

Terumo Kabushiki Kaisha

St Jude Medical, Atrial Fibrillation Division, Inc

Pulmonx Corporation

Medtronic, Inc.

Stryker Corporation

Edwards Lifesciences Corporation

Advanced Cardiovascular Systems, Inc.

Alcon, Inc.

Medtronic Ardian Luxembourg S.a.r.l.

Hanson S Gifford, Iii

Mark E Deem

Bernard H Andreas

Douglas S Sutton

Ronald G French

Lee R Bolduc

John Henry Stevens

Stephen A Boyd

Eugene De Juan, Jr

Wesley D Sterman

Paul C DiCesare

William A Holmes

Peter F Costa

Jeffrey A Stein

Vivek Shenoy

Cary J Reich

Douglas Sutton

James I Fann

Sunmi Chew

Doug Sutton

Alan R Rapacki

William S Peters

Michi E Garrison

John H Morriss

Alex T Roth

Martin S Dieck

Stephen W Boyd

Jeffry J Grainger

Michael J Hendricksen

William W Malecki

Jose D Alejandro

Darin Charles Gittings

Brian S Donlon

Allan R Will

Matthias Vaska

Martin L Mayse

Daniel C Rosenman

Kenneth N Horne

Dan Francis

Conor M Hanley

Timothy R Machold

Eric A Goldfarb

David W Snow

Kent D Dell

Jessi E Johnson

Matthew McLean

Ferolyn T Powell

Neil S Zimmerman

Karun D Naga

Ivan Sepetka

Steven Charles Dimmer

Yair Alster

Brian Benjamin Martin

Thomas Weisel

James Flom

Antony Jonathan Fields

Michael Barrett

Ronald Ray Hundertmark

Peter M Wilson

Philip Christopher Evard

John Anthony Scholl

K Angela Macfarlane

Scott H Miller

Michael Luna

Denise Marie Zarins

David Mark Taylor

Craig R Gerbi

Jean-Pierre Dueri

Maria G Aboytes

Erik Thai

Ben F Brian, Iii

Son M Gia

Gary B Weller

Richard L Lindstrom

James R Gannoe

Robert George

David R Tholfsen

Jan Komtebedde

John G McCutcheon

David Sierra

Mark Gelfand

Howard R Levin

John B Simpson

Steven W Kim

Scott Clinton Anderson

Benjamin J Clark

Jonathan L Podmore

Richard L Mueller

John William Sliwa

James E Chomas

Nicolas Zadno

Randolph E Campbell

John Edwards Crowe

Kathleen Cogan Farinas

Omer Rafaeli

Matt McLean

Peter Tachi Callas

Timothy Edward Ciciarelli

Robert L Lathrop, Jr

Tricuspid valve repair devices and associated systems and methods are disclosed herein. A tricuspid valve repair device configured in accordance with embodiments of the present technology can include, for example, a coaptation member configured to be positioned between one or more native leaflets of the tricuspid valve to at least partially fill a space between the native leaflets. The tricuspid valve repair device can further include one or more fixation mechanisms for securing the coaptation member in position between the leaflets. The fixation mechanisms can include clip mechanisms, lock mechanisms, stabilization members, anchors, and/or other structures configured to engage cardiac anatomy local to or remote from the tricuspid valve, such as the native leaflets, the tricuspid valve annulus, the right ventricular outflow tract, the superior vena cava, the inferior vena cava, and so on.

Tricuspid valve repair devices and associated systems and methods

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and/or left ventricular pressure.

Implantable coaptation assist devices with sensors and associated systems and methods

Devices and methods are disclosed herein for accessing the hip joint. A first device can be securely attached to the capsule of a joint. The first device can tent the capsule to increase the volume of the peripheral compartment. A second device can be biased against the first device to pierce the tented capsule and create a portal. Devices and methods are also disclosed herein for distending the capsule of a joint. A distention device may access a portal established within the capsule. The distention device can expand the capsule by applying an expansive force within the peripheral compartment. The distention device can maintain distention of the peripheral compartment while other devices access the joint.

Methods and devices for accessing and retracting a capsule of a joint

A heart valve repair device may include a support configured to extend through a native annulus of a native heart valve, wherein the support comprises an upstream portion and a downstream portion; an annular expandable retainer extending from the upstream portion of the support, and an arm extending from the downstream portion of the support. The annular expandable retainer may include a C-shaped cross-section that is open inwardly. The arm may be configured to reach behind a leaflet of the native heart valve and sandwich the leaflet between the arm and the support.

Devices, systems and methods for heart valve replacement

The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents

Systems and methods are provided for removal of clot material from a treatment site in a blood vessel, particularly in venous vasculature. A treatment device () can include a core member () having a distal portion () and an inner coil () surrounding the distal portion of the core member. A helical outer member () surrounds at least a portion of the inner coil, and a sheet of flexible material () extends between the inner coil and the helical outer member, such that the sheet extends helically around the inner coil to provide a surface for clot engagement at the treatment site.

Mechanical venous clot retrieval

Wireless, variable inductance and resonant circuit-based vascular monitoring devices, systems, methodologies, and techniques, including specifically configured anchoring structures for same, are disclosed that can be used to assist healthcare professionals in predicting, preventing, and diagnosing various heart-related and other health conditions.

Wireless resonant circuit and variable inductance vascular monitoring implants and anchoring structures therefore

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

Glaucoma treatment device

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Implantable depots for the controlled release of therapeutic agents

Systems, delivery devices, and methods to treat to ablate, damage, or otherwise affect tissue. The treatment systems are capable of delivering a coolable ablation assembly that ablates targeted tissue without damaging non-targeted tissue. The coolable ablation assembly damages nerve tissue to temporarily or permanently decrease nervous system input. The system, delivery devices, and methods can damage tissue and manage scarring and stenosis.

Systems, apparatuses, and methods for treating tissue and controlling stenosis

An implant in accordance with an embodiment of the present technology includes proximal and distal end portions spaced apart from one another along a longitudinal axis and configured to be deployed at first and second airways, respectively, of a bronchial tree, the second airway being of a greater generation than the first airway. The implant includes a wire extending along a wire path within a tubular region coaxially aligned with the longitudinal axis. The wire includes first and second legs alternatingly disposed along the wire path and extending distally and proximally, respectively, in a circumferential direction about the longitudinal axis. The implant is configured to transition from a low-profile delivery state to an expanded deployed state at a treatment location and to allow mucociliary clearance from immediately distal to the implant to immediately proximal to the implant while the in deployed at the treatment location.

Endobronchial implants and related technology

Devices, systems, and methods for treating a blood flow passage are discloses herein. In one example, a treatment device includes an expandable element configured to be positioned within the passage and a reinforcing element. The expandable element may have an expanded configuration in which the expandable element defines a lumen therethrough. The reinforcing element may be positioned within the lumen of the expandable element. The reinforcing element may be coupled to the expandable element such that expansion of the expandable element causes the reinforcing element to radially expand, thereby creating a perfusion lumen through the device.

Vascular treatment devices and associated systems and methods of use

Systems and methods are disclosed that provide for regular, periodic or continuous monitoring of fluid volume based on direct measurement of an inferior vena cava (IVC) physical dimension using a wireless measurement sensor implanted in the IVC. By basing diagnostic decisions and treatments on changes in an IVC physical dimension, information on patient fluid state is available across the entire euvolemic range of fluid states, thus providing earlier warning of hypervolemia or hypovolemia and enabling the modulation of patient treatments to permit more stable long-term fluid management.

Systems and methods for self-directed patient fluid management

Methods and apparatus are provided for pulsed electric field (PEF) neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, an apparatus includes an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers. With the electrode(s) passing from an intravascular position to an extravascular position prior to delivery of the PEF, a magnitude of applied voltage or energy delivered via the electrode(s) and necessary to achieve desired neuromodulation may be reduced relative to an intravascular PEF system having one or more electrodes positioned solely intravascularly. The methods and apparatus may, for example, be used to modulate one or more target neural fibers that contribute to renal function.

Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach

Delivery systems for placing an implantable cardiac device at a native comprising a delivery catheter and an attachment assembly. The delivery catheter can include a proximal portion and a distal portion, and the attachment assembly can be at the distal portion of the delivery catheter. The attachment assembly can include arm pairs in which individual arm pairs include a first arm with connector and a second arm with a retainer. Each first arm extends along a corresponding second arm, and the first arm and/or the second arm in each arm pair moves relative to the other from a locked position to a released position. In the locked position, the retainer interfaces with the connector to maintain engagement between the implantable device and the connector. In the released position, the retainer is positioned relative to the connector such that the implantable device can disengage the connector.

Delivery systems for cardiac valve devices

Growing community of inventors

Woodside, CA, United States of America

Hanson S Gifford, Iii